Open AccessThe 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma
Author(s) -
Abel Jarell,
Basil S. Skenderis,
Larry D Dillon,
Kelsey Dillon,
Brian J. Martin,
Ann P. Quick,
Jennifer J. Siegel,
Briana B Rackley,
Robert W. Cook
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0996
Subject(s) - medicine , melanoma , hazard ratio , oncology , stage (stratigraphy) , metastasis , sentinel node , biopsy , cancer , confidence interval , cancer research , breast cancer , paleontology , biology
Aim: Sentinel node biopsy is a prognostic indicator of melanoma recurrence. We hypothesized that adding the primary melanoma molecular signature from the 31-gene expression profile (31-GEP) test could refine the risk of recurrence prognosis for patients with stage I–III melanoma. Materials & methods: Four hundred thirty-eight patients with stage I–III melanoma consecutively tested with the 31-GEP were retrospectively analyzed. The 31-GEP stratified patients as low-risk (Class 1A), intermediate-risk (Class 1B/2A) or high risk (Class 2B) of recurrence or metastasis. Results: The 31-GEP significantly stratified patient risk for recurrence-free survival (p < 0.001), distant metastasis-free survival (p < 0.001) and melanoma-specific survival (p < 0.001) and was a significant, independent predictor of metastatic recurrence (hazard ratio: 5.38; p = 0.014). Conclusion: The 31-GEP improves prognostic accuracy in stage I–III melanoma.